Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical, Inc. (ISRG) is a medical technology company headquartered in Sunnyvale, California and known for its role in minimally invasive care and robotic-assisted surgery. Its news flow frequently centers on developments related to the da Vinci surgical systems and the Ion endoluminal system, along with financial performance updates and regulatory milestones.
Investors and healthcare professionals following ISRG news can expect regular earnings announcements, where the company reports quarterly and preliminary annual financial results. These updates typically highlight worldwide procedure growth on da Vinci and Ion platforms, changes in the installed base of systems, and trends in systems, instruments, and accessories revenue.
Another major category of Intuitive news involves product clearances and platform enhancements. Recent press releases describe FDA clearances expanding indications for the da Vinci Single Port (SP) system to additional general surgery procedures, clearance of advanced energy instruments such as Vessel Sealer Curved, and regulatory certifications for the da Vinci 5 system in regions including the European Union and Japan. News also covers software and digital features for da Vinci 5, such as Force Gauge, In-Console Video Replay, and Network CCM for remote software updates.
Intuitive’s news feed also includes updates on the Ion endoluminal system, including FDA-cleared software releases that introduce artificial intelligence across Ion’s navigational workflow and integrate advanced imaging capabilities to support lung biopsy procedures. Additional stories describe demonstrations of telesurgery capabilities using da Vinci 5 and collaborations with hospitals adopting newer platforms.
For those tracking ISRG, this news page provides a consolidated view of company press releases, allowing readers to monitor procedure and system trends, regulatory progress, and technology updates that shape Intuitive’s position in robotic-assisted surgery and minimally invasive care.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Intuitive (Nasdaq: ISRG) reported strong Q1 2023 financial results, with revenue of $1.70 billion, a 14% increase compared to Q1 2022. The growth was driven by a 26% rise in da Vinci procedures despite ongoing COVID-19 disruptions in China. The company placed 312 da Vinci Surgical Systems, maintaining a steady growth of its installed base to 7,779 systems, a 12% increase year-over-year. Non-GAAP net income was $437 million, or $1.23 per diluted share, up from $413 million, or $1.13 per diluted share in Q1 2022. However, GAAP net income decreased slightly to $355 million from $366 million year-over-year. The company ended the quarter with $6.58 billion in cash and cash equivalents, reflecting share repurchases of $350 million.
Intuitive (Nasdaq: ISRG) announced fourth-quarter 2022 results, reporting revenue of $1.66 billion, a 7% increase from Q4 2021. Worldwide da Vinci procedures rose approximately 18%, but were affected by COVID-19 surges in China. The company placed 369 da Vinci Surgical Systems, down 4% from the previous year, while the installed base grew to 7,544 systems, a 12% increase.
GAAP net income was $325 million or $0.91 per diluted share, down from $381 million or $1.04 per share in Q4 2021. The company repurchased $1 billion in stock during the quarter, ending with $6.74 billion in cash and equivalents.
Intuitive (Nasdaq: ISRG) announced preliminary financial results for Q4 and full year 2022. Fourth quarter revenue reached approximately $1.66 billion, up 7% year-over-year, while full-year revenue was about $6.22 billion, a 9% increase. The company experienced an 18% growth in worldwide da Vinci procedures for Q4 2022, despite disruptions from COVID-19 in China. However, the placement of da Vinci Surgical Systems declined by 4% in Q4 and 6% for the year. The company anticipates a 12% to 16% increase in procedures for 2023.
Intuitive has been recognized as the largest provider of robotic-assisted surgical technology training accredited by the Royal College of Surgeons of England. This global accreditation highlights Intuitive's commitment to excellence in surgery-related education, having trained over 60,000 surgeons worldwide on their da Vinci Surgical Systems. The recognition confirms the quality and safety of their educational programs, ensuring surgeons confidently adopt new technologies. Dr. Gillian Duncan emphasized the importance of high training standards in maximizing robotic surgery benefits.
Intuitive (Nasdaq: ISRG) reported Q3 2022 revenue of $1.56 billion, marking an 11% increase from $1.40 billion in Q3 2021. Worldwide da Vinci procedures grew by approximately 20%, rebounding from COVID-19 disruptions. Despite placing 305 da Vinci Surgical Systems, down 9% from 336 systems in Q3 2021, the company’s installed base rose to 7,364 systems, a 13% increase. GAAP net income fell to $324 million ($0.90/share) from $381 million ($1.04/share) in the prior year.
The company repurchased $1 billion of common stock and ended the quarter with $7.39 billion in cash and investments.
Intuitive has received clearance from Japan's Ministry of Health for its da Vinci SP surgical system, making it the first single-port robotic surgical system approved in the country. This system will facilitate general, thoracic (non-cardiac), urologic, gynecological, and head and neck surgeries. With this approval, Intuitive aims to enhance minimally invasive surgical options for Japanese surgeons. The company anticipates launching the SP system soon, complementing its existing multi-port systems and expanding access to robotic-assisted procedures.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
